Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1992
- Registration Number
- NCT00902928
Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients
- Conditions
- Interventions
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 198
- Registration Number
- NCT00894283
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study
- Conditions
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- Robert Welsh
- Target Recruit Count
- 44
- Registration Number
- NCT00882635
- Locations
- 🇨🇦
Southlake, NewMarket, Ontario, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 11
- Registration Number
- NCT00878826
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 641
- Registration Number
- NCT00839826
Enoxaparin and/or Minocycline in Acute Stroke
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 6
- Registration Number
- NCT00836355
- Locations
- 🇺🇸
New York University Langone Medical Center, New York, New York, United States
🇺🇸Bellevue Hospital Center, New York, New York, United States
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 316
- Registration Number
- NCT00793234
- Locations
- 🇺🇦
Cherkasska Regional Hospital. Department of Orthopedics and Traumatology., Cherkassy, Ukraine
🇷🇺Saint Petersburg State Healthcare Institution "Municipal Multi-Speciality Hospital No. 2", Saint Petersburg, Russian Federation
🇺🇦Ivano-Frankіvsk Regional Clinical Hospital, Department of ortopedics and traumatology., Ivano-Frankivsk, Ukraine
Tirofiban and Enoxaparin in High Risk Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- The Prince Charles Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00790387
- Locations
- 🇦🇺
The Prince Charles Hospital, Brisbane, Queensland, Australia
Chemotherapy With or Without Enoxaparin in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- CONKO-Studiengruppe
- Target Recruit Count
- 312
- Registration Number
- NCT00785421
- Locations
- 🇩🇪
Universitätsmedizin - Berlin - Charite, Berlin, Germany
Anticoagulation Post Laparoscopic Splenectomy
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2009-06-24
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 35
- Registration Number
- NCT00769873
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦Grey Nuns Hospital, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.